Rock Springs Capital ABCM Position
ExitedRock Springs Capital exited their position in Abcam plc (ABCM) in Q4 2023, after holding the stock for 4 quarters.
The position was first reported in Q1 2023 and has been tracked across 4 quarterly 13F filings.
1 other tracked fund also holds ABCM.
About Abcam plc
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.
Full company profile →Rock Springs Capital ABCM Position History
Frequently Asked Questions
Does Rock Springs Capital own ABCM?
No. Rock Springs Capital exited their position in Abcam plc (ABCM) in Q4 2023. They previously held the stock for 4 quarters.
How many hedge funds own ABCM?
1 specialist biotech hedge fund currently holds ABCM, including Driehaus Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy ABCM?
Rock Springs Capital's position in ABCM was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's ABCM position increasing or decreasing?
Rock Springs Capital completely exited their ABCM position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ABCMCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →